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Abstract: Gestational diabetes (GDM) is hyperglycemia that is recognized for the first time during
pregnancy. GDM is associated with a wide range of short- and long-term adverse health consequences
for both mother and offspring. It is a complex disease with a multifactorial etiology, with disturbances
in glucose, lipid, inflammation and gut microbiota. Consequently, its management is complex,
requiring patients to self-manage their diet, lifestyle and self-care behaviors in combination with use
of insulin. In addition to nutritional recommendations for all pregnant women, special attention
to dietary carbohydrate (CHO) amount and type on glucose levels is especially important in GDM.
Dietary CHO are diverse, ranging from simple sugars to longer-chain oligo- and poly- saccharides
which have diverse effects on blood glucose, microbial fermentation and bowel function. Studies
have established that dietary CHO amount and type can impact maternal glucose and nutritional
recommendations advise women with GDM to limit total intake or choose complex and low glycemic
CHO. However, robust maternal and infant benefits are not consistently shown. Novel approaches
which help women with GDM adhere to dietary recommendations such as diabetes-specific meal
replacements (which provide a defined and complete nutritional composition with slowly-digested
CHO) and continuous glucose monitors (which provide unlimited monitoring of maternal glycemic
fluctuations) have shown benefits on both maternal and neonatal outcomes. Continued research is
needed to understand and develop tools to facilitate patient adherence to treatment goals, individualize
interventions and improve outcomes.
Keywords: gestational diabetes mellitus; pregnancy; dietary carbohydrates; diabetes-specific formula;
continuous glucose monitoring
1. Introduction
Gestational diabetes (GDM) is one of the most common adverse medical conditions of pregnancy,
and its prevalence is rising as part of the global diabetes pandemic, both in developed and developing
countries. GDM is complex and multifactorial, with several aspects contributing to explain its
pathophysiology, although this is not fully clarified yet.
Nutrition in general and some particular nutritional compounds, such as carbohydrates (CHO)
and fiber, contribute to regulate glycemic index and glycemic response, and consequently can influence
establishment and evolution of gestational diabetes during pregnancy as well as risk of clinical
outcomes both in the mother and the infant. Consequently, nutrition may be a key tool for prevention
and management of gestational diabetes.
Nutrients 2020, 12, 385; doi:10.3390/nu12020385 www.mdpi.com/journal/nutrients
Nutrients 2020, 12, 385 2 of 17
After a brief overview of the prevalence, short- and long-term health consequences and
pathophysiology of GDM, this review will focus on what is known about the role of dietary
carbohydrates in its prevention and treatment. Nutrition recommendations from professional health
groups will be summarized, with a focus on the specific research on dietary carbohydrate quantity and
quality that informs the basis for carbohydrate recommendations. Finally, the use of novel approaches
such as specialized nutritional supplements and continuous glucose monitoring to help patients adhere
to treatment goals will be discussed.
2. Background
2.1. Prevalence Worldwide and the Trends over the Past Decade
Gestational diabetes (GDM) is hyperglycemia that is recognized for the first time during pregnancy.
It encompasses undiagnosed type 2 diabetes and hyperglycemia which develops later in pregnancy [1].
It is one of the most common adverse medical conditions of pregnancy, and its prevalence is rising as
part of the global diabetes pandemic. It is estimated that GDM affects around 21.3 million or one in
six live births in 2017 [2]. Studies have shown that GDM increases with a faster rate in lower- and
middle-income countries than high-income countries, especially over the past decade [1–3]. Yan et al.
reported the GDM prevalence increased from 15.5% to 19.9% from 2012 to 2017 in Xiamen, China [1].
Lavery et al. reported about 5.5% increase in GDM prevalence in the USA over a 20-year period from
1990 to 2010 [3]. A study in Spain examining the trend of GDM prevalence showed an increase of 4.8%
over a period of 9 years from 2006 to 2015 [4]. According to the International Diabetes Federation,
South East Asia had the highest prevalence of GDM with 26.6% followed by Middle East/North Africa
(18%), Europe (14%) and Africa (9.5%) [2]. Because of significant health and economic burdens, the
increasing prevalence of GDM in most populations has become a global health challenge, especially in
low- and middle-income countries.
2.2. Short- and Long-Term Health Consequences for Mothers and Offspring
In the short-term, GDM increases pregnancy and birth complications. Women with GDM are
more likely to develop gestational hypertension and preeclampsia. A population-based retrospective
cohort including 426,296 deliveries over a 10-year period reported a 90% higher risk of preeclampsia
in women with GDM than those without GDM [5]. Pre-pregnancy obesity, excessive gestational
weight gain and poor glycemic control are linked with greater risk of gestational hypertension and
pre-eclampsia in women with GDM [6]. GDM is considered an independent risk factor for newborn
large for gestational age (LGA) and macrosomia. A meta-analysis reported the pooled odds ratio of
macrosomia was 5.5 folds higher in women with GDM than those without GDM [7]. Additionally,
the risk for LGA increases as fasting and two-hour post-oral glucose tolerance test (OGTT) glucose
increase during pregnancy. Farrar et al. studied the association between blood glucose and perinatal
outcomes in a meta-analysis involving up to 207,172 women [8]. They found that the odds ratios for
LGA per 18 mg/dL increase in fasting and two-hour post-OGTT glucose concentrations were 2.15
(95% confidence interval 1.60 to 2.91) and 1.20 (1.13 to 1.28), respectively. Infants born LGA and
with macrosomia increased instrumental delivery, caesarean section, premature birth and shoulder
dystocia [8,9]. Such pregnancy and neonatal complications were associated with delayed initiation of
breastfeeding, lower rates of breastfeeding and breastfeeding duration in women with GDM [10,11].
Because breastfeeding has been shown to be a protective factor for the development of T2DM in GDM
mothers and in their offspring [12,13], suboptimal breastfeeding has an implication in future health
risk for both mother and child.
Additionally, these pregnancies and neonatal complications impose substantial economic burdens.
A burden-of-illness study on GDM conducted in China has shown that the cost of a pregnancy
with GDM was 95% more than for a pregnancy without GDM, due to additional expenses for GDM
diagnosis and management, and for mother and neonatal complications. With a number around
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2.9 million pregnancies affected by GDM in 2015, the estimated annual economic burden of GDM was
an international $5.59 billion from incremental direct medical costs [14].
In the long-term, GDM increases the risk—in both mother and offspring—of type 2 diabetes,
metabolic syndrome and obesity. In their systematic review, Hopmans et al. [15] showed that the
increased risk of type 2 diabetes and cardiovascular disease was 13 times and two times higher,
respectively, in women with GDM when compared with healthy control [15]. In a recent meta-analysis,
Kramer et al. investigated the association between GDM and long-term cardiovascular disease in
5,390,591 women. They found that GDM was associated with a 2.3-fold increased risk of cardiovascular
events in the first decade postpartum when compared with women without GDM [16].
In children, intrauterine exposure to GDM increases the risk for overweight/obesity and abnormal
glucose tolerance. A total of 26,509 children born to mothers with and without GDM were included in
a meta-analysis to investigate the association of maternal hyperglycemia exposure during pregnancy
with obesity and abnormal glucose tolerance in offspring [17]. The rate of obesity or overweight in
children aged 2–17 years was 1.35 times higher in the offspring of GDM mothers. This increased
risk was highest in the age group of 11 years and above [17]. Additionally, the children of women
with GDM had higher two-hour plasma glucose through early adulthood (pooled MD: 0.43 mmol/L,
95% CI: 0.18–0.69), [17]. Another study reported a four-fold increased risk for metabolic syndrome in
children from GDM mothers, with the risk increasing significantly with increasing maternal fasting
and two-hour blood glucose [18]. Overwhelmingly, GDM has significant and adverse implications on
the future burden of non-communicable diseases in both mother and offspring.
3. Key Aspects of GDM Pathophysiology
GDM is a complex disease with a multifactorial etiology; however, the exact mechanisms involved
in its pathophysiology are not fully clarified [19]. The purpose of this section is to review the key
aspects implicated in its onset and recent advances regarding GDM.
3.1. Glucose and Lipid Metabolism
During normal pregnancy, the body undergoes numerous metabolic and immunological changes
that are designed to maintain maternal and fetal health. One of the major metabolic changes is related
to glucose metabolism [20]. Glucose metabolism changes according to the course of pregnancy and
fetal needs. At first, fasting glucose levels drop, likely due to both increased maternal blood volume
and the fetal use. To adjust to this physiological change, pancreatic β cells suffer hyperplasia and
hypertrophy to increase insulin secretion, maintaining maternal euglycemic state and preserving
the embryo [19]. Another common change that occurs during normal pregnancy is a reduction of
insulin sensitivity and an increase of insulin resistance. This is normally seen in normal pregnancies,
presumably to spare the glucose for the fetus, and can be attributed to the production of placental
hormones such as estrogens, progesterone, placental lactogen, placental growth hormone, leptin and
cortisol and may be intensified by genetic susceptibility and/or mother’s lifestyle [21].
Exacerbated peripheral insulin resistance during pregnancy and poor β-cell adaptation likely
contribute to GDM. Decreased insulin-stimulated glucose disposal by 22% has been observed in GDM
when compared with normal pregnancy [22]. As compared to normal pregnancy, impaired skeletal
muscle glucose uptake in women with GDM is usually explained by the failure of insulin signaling,
due to an additional decrease in tyrosine phosphorylation of the insulin receptor, which inhibits insulin
signaling from activating GLUT4 translocation. Decreased insulin-stimulated glucose uptake can
trigger failure of the β-cell and hyperglycemia in GDM [23]. Indeed, β-cell failure or insufficiency were
described by Buchanan et al. [24], showing that insulin secretion increases throughout pregnancy in
both women with and without GDM, but beginning at a lower starting point in women with GDM.
Along with changes in insulin resistance and the subsequent response of pancreatic β-cells,
hepatic glucose production is also significantly altered in women with GDM. Basal endogenous glucose
production increases in a similar way in women with and without GDM [22]. However, in late gestation
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the ability of insulin to suppress gluconeogenesis was lower in GDM as compared to the normal
pregnant women.
Major changes in lipid metabolism also occur during pregnancy [25]. In the mother, during the
early stage of pregnancy there is an increase in the fat depot accumulation as result of increased lipid
synthesis and hyperphagia. During this period, these lipidic disturbances are caused by enhanced
adipose insulin responsiveness that facilitates the accumulation of circulating lipids in the adipose tissue.
However, in late gestation, and as consequence of the insulin resistant condition, adipose lipolytic
activity is increased with a parallel reduction in the lipoprotein lipase activity and fatty acid synthesis
in the adipose tissue. These changes determine the development of maternal hypertriglyceridemia in
normal pregnancy [26]. In GDM, the pronounced peripheral resistance and inadequate β-cell function
cause these alterations to be exacerbated, resulting in enhanced lipolysis and ketogenesis. Under these
circumstances, the dyslipidemia in diabetic pregnancy compared with normal pregnancy actively
contributes to the chronic maternal insulin resistance and increases the exposure of lipids to the fetus,
contributing to fat accumulation, macrosomia and LGA. Enhanced levels of small size and dense
LDL particles have been consistently found in GDM [27] regardless the circulating concentrations of
LDL-cholesterol [28].
3.2. Inflammation
A tightly-regulated balance between pro- and anti-inflammatory cytokines is believed to be
necessary for normal implantation, trophoblast invasion and placentation [29]. In early and
late-pregnancy, elevated secretion of pro-inflammatory cytokines (TNF- α and Interleukin (IL)-6)
and reduced levels of anti-inflammatory cytokines (Il-10 and IL-4) are observed in women developing
GDM [30], suggesting that inflammation may be involved in the development of insulin resistance
associated with GDM. Pro-inflammatory cytokines can alter the insulin signaling pathway by
dampening insulin receptor (IR) tyrosine kinase activity, amplifying serine phosphorylation of IRS-1,
or by altering the STAT3-SOCS3 pathway. In a study by Kirwan et al., 2002 [31] and corroborated by
Catalano and coworkers, 2014 [22] they showed that plasma TNF α was the most strongly correlated
factor with insulin sensitivity. Similarly, placental gene expression of TNF-α, IL-1β and their receptors
have been reported to be increased in GDM. Besides that, in a study published in October 2019 [32],
another pro-inflammatory cytokine (IL-34) which operates as a ligand for colony-stimulating factor-1
receptor (CSF-1R) was discovered to contribute to the apoptosis of pancreatic β cells, playing a crucial
role in the development of GDM [32].
3.3. Gut Microbiota
The normal gut microbiota composition appears to undergo important shifts during normal
pregnancy. In late pregnancy, the gut microbiota pattern resembles the disruptive gut microbiota
composition to that of adults with type 2 diabetes [33]. Individuals with insulin resistance show
significant changes in the Firmicutes/Bacteroidetes ratio, with a reduction in butyrate-producing bacteria
compared to healthy individuals [34]. Fugmann et al. (2015) [35] analyzed stool microbiota both in
insulin resistant women with a recent history of GDM and women after a normoglycemic pregnancy.
They found that women with a Prevotellaceae-dominated intestinal microbiome were overrepresented
in the GDM group. Similarly, Bassols et al. (2012) [36] extracted and analyzed microbial DNA and
RNA from the appendix contents of eight insulin resistant and eight insulin-sensitive obese subjects.
They concluded that gut RNA microbial profile varies in accordance with insulin action. Recently,
Crusell et al. (2018) [33] showed that gut microbiota of women with GDM are distinct from microbiota
changes of normal pregnant women, including phylum and genus levels. In this study, there was a
difference in the abundance of 17 species level operational taxonomic units (OTUs) in GDM compared
with the normoglycemic pregnant women. Although different studies report the link between the gut
microbial profile and insulin resistance, the potential pathophysiological role of gut bacteria in GDM
remains still unknown.
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4. Role of Dietary Carbohydrates in GDM
Dietary carbohydrates (CHO) are an important energy source for both mother and fetus, and all
pregnant women need at least 175 g of CHO, including 28 g of fiber per day [37]. However, for women
with GDM, there is an additional need to pay careful attention to amount and type of CHO as it is
well-established that dietary CHO have the greatest impact on blood glucose. Dietary CHO are diverse
in structure with variable effects on blood glucose responses and other physiological outcomes [38].
Many dietary CHO (glucose, sucrose, cooked starches found in pastas, potatoes, white bread) are
readily digested and absorbed in the small intestines, and these contribute to a rapid increase in blood
glucose. Some dietary CHO have a structure that makes them resistant to digestion—or completely
non-digested—and these result in a small and/or slower increase in blood glucose (e.g., low glycemic
index, LGI). Components of CHO that are not digested (fiber) pass through the small and large intestine
where they can provide important physiological benefits such as stimulate incretin production, serve
as an energy source for colonic microbiota, and promote normal bowel movements.
Early studies established that elevated postprandial glucose responses contribute to an increased
glucose transport to the fetus and hyperglycemia correlates significantly with infant size and/or
adiposity [39,40]. Studies also have established that maternal glucose responses can be markedly
influenced by the total amount of CHO [39,41,42] or the type of CHO [43] consumed. Evidence from
preclinical studies [44,45] using animals models of gestational diabetes shows that negative effects of
feeding high-GI sucrose and maltodextrin on the pathophysiology of GDM in dams and their offspring
can be reversed by substituting these rapidly-metabolized CHO with more slowly-digesting CHO
(i.e., isomaltulose and resistant maltodextrins). As a result, in order to improve maternal fasting and
postprandial glucose during GDM, current dietary guidelines recommend either to restrict CHO intake or
to replace high glycemic/rapidly-digesting (HGI) CHO with those that are more slowly digesting (Table 1).
However, as commented in numerous publications [46–49], these dietary recommendations are
limited by the lack of robust evidence. Randomized nutritional intervention trials that have evaluated
dietary strategies focusing on CHO in women with [50–58] or at risk of [59–62] GDM have not shown
consistent benefits on maternal or infant outcomes. The details of the studies, their dietary interventions
and outcomes have been critically reviewed in other recent publications [46–49]. Overall, it is widely
viewed that these studies suffer from small sample size and thus are underpowered and observed
benefits on LGA or other infant and maternal outcomes are not consistent across studies. The most
current Cochrane analysis [63] did not show significant maternal and/or infant benefits; in contrast,
Yamamoto et al. [64] focused their primary analysis on maternal glycemic outcomes and concluded that
interventions that improved maternal glycemic control would improve infant birthweight outcomes.
In agreement was another meta-analysis by Wan et al. [65] who focused their meta-analysis on
dietary intervention strategies to include all Chinese-language studies. Their conclusion was that
CHO-modified diets were associated with improved glycemic control and infant birth outcomes in
ethnic Chinese women with GDM.
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Table 1. Nutrition Recommendations for gestational diabetes mellitus (GDM).
Organization General Recommendation for GDM Carbohydrate-SpecificRecommendations Reference/Link
International Federation of Gynecology
and Obstetrics
Caloric intake should be calculated
based on pre-pregnancy BMI and
desirable weight gain; Caloric intake
may be reduced by 30%, but not below
1600−1800 kcal/d; for women with
diabetic nephropathy, protein may be
lowered to 0.6−0.8 g/kg ideal
body weight.
Carbohydrate intake should be limited to
35%–45% of total calories, with a
minimum of 175 g CHO per day,
distributed in three small-to-moderate
sized meals and 2−4 snacks.
M. Hod et al./International Journal of
Gynecology and Obstetrics 131 S3 (2015)
S173–S211
Endocrine Society
Medical nutrition therapy is
recommended for all pregnant women
with overt or gestational diabetes to help
achieve and maintain desired glycemic
control while providing essential
nutrient requirements.
Carbohydrate should be limited to 35%
to 45% of total calories, distributed in 3
small-to-moderate-sized meals and 2 to 4
snacks including an evening snack
Blumer I., Hadar E., Haddan DR., et al.,
Diabetes and Pregnancy: An Endocrine
Society Clinical Practice Guideline. J Clin
Endo Metab 2013:98:4227–4249.
American College of Obstetrics and
Gynecologists
Eat regular meals throughout the day;
three meals and two–three snacks per
day. Gain healthy amount of weight.
Complex CHO are recommended over
simple CHO because they are digested
more slowly, are less likely to produce
significant postprandial hyperglycemia,
and potentially reduce insulin resistance.
Obstetrics & Gynecology. 131(2):e49–e64,
FEBRUARY 2018 OI:
10.1097/AOG.0000000000002501 PMID:
29370047 Issn Print: 0029–7844
Publication Date: February 2018
National Institute for Health and Care
Excellence (NICE) guidelines
Advise women to eat a healthy diet
during pregnancy, refer all women with
gestational diabetes to a dietitian.
Foods with a low glycemic index should
replace those with a high glycemic index.
NICE National Institute for Health and
Care Excellence Guideline. Diabetes in
pregnancy: Management from
preconception to the postnatal period.
Published: 25 February 2015
www.nice.org.uk/guidance/ng3
Diabetes Canada
Meal planning for women with GDM
should emphasize a healthy diet during
pregnancy.
Women should consume a minimum of
175 g/day of CHO, distributed over 3
moderate-sized meals and 2 or more
snacks (1 of which should be at bedtime),
replacing high-GI foods with
low-GI ones.
Feig DS, Berger H., Donovan L., et al.,
Diabetes and Pregnancy. Diabetes Canada
2018. Clinical Practice Guidelines for the
Prevention and Management of Diabetes in
Canada: Pharmacologic Glycemic
Management of Type 2 Diabetes in Adults.
Can J Diabetes 2018;42(Suppl 1):S255–S282.
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Table 1. Cont.
Organization General Recommendation for GDM Carbohydrate-SpecificRecommendations Reference/Link
American Academy of Nutrition and
Dietetics
A registered dietitian nutritionist (or
international equivalent) should provide
Medical Nutrition Therapy that includes
an individual nutrition prescription and
nutrition counseling for all women
diagnosed with GDM.
All pregnant women should eat a
minimum of 157 g CHO and 28 g fiber.
The amount and type of CHO should be
individualized based on nutrition
assessment, treatment goals, blood
glucose response and patient needs.
Three meals and 2 or more snacks helps
to distribute CHO intake and reduce
postprandial blood glucose elevations.
Duarte Gardea et al., Academy of
Nutrition and Dietetics Gestational
Diabetes Evidence-Based Nutrition
Practice Guideline Journal of the
Academy of Nutrition and Dietetics.




The food plan should be based on a
nutrition assessment with guidance from
the Dietary Reference Intakes.
All pregnant women should eat a
minimum of 175 g total CHO and 28 g
fiber. For women with GDM, the amount
and type of CHO will impact glucose
levels, especially post-meal excursions.
American Diabetes Association. 14.
Management of Diabetes in Pregnancy:
Standards of Medical Care in Diabetes.
2019 Diabetes Care 2019;42(Suppl. 1):
S165–S172|
https://doi.org/10.2337/dc19-S014
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Studies have evaluated nutritional interventions for preventing GDM [59–62,66] Most have
combined increasing physical activity with energy restriction through reducing on the quantity and/or
changing the type of CHO to reduce or slow weight gain during early pregnancy. Studies and their
findings are diverse. In the LIMIT trial [59] over 2000 pregnant overweight and obese pregnant women
were randomized before 20 weeks of gestation to standard of care or an intensive lifestyle arm including
advice to reduce intake of refined CHO. Babies born to women in the intensive lifestyle intervention
were significantly less likely to be LGA, have respiratory distress syndrome and had shorter hospital
stays. In the GI Baby 3 study of 139 women at high risk of GDM [60], those following low-GI diet
advice required less insulin to maintain normoglycemia (p = 0.007) compared to a group following
a high-GI diet. Walsh et al. [61], in the ROLO study, evaluated 800 women in their second half of
pregnancy who were at high risk for GDM having previously delivered an infant weighting greater
than 4 kg. Pregnant women who were randomized to receive low-GI diet advice had significantly
lower gestational weight gain and less maternal glucose intolerance compared to those following
standard of care. However, the incidence of LGA infants was not reduced. The UPBEAT study [0]
randomized 1555 obese women to receive a standard of care or an intensive behavioral intervention
to increase physical activity and improve diet quality with an emphasis on low-GI foods. Despite
improvements in gestational weight gain, the intervention was not associated with additional benefits.
Most recently, Zhang et al., [67] reviewed the effects of low-GI diets in all pregnant women,
both those having healthy pregnancies, at risk for GDM, and those with GDM. In a total of 11 trials
involving 1985 women, low-GI diets significantly reduced fasting and two-hour postprandial glucose
level. Pregnant women following low-GI diet advice had a higher risk of delivery of low for gestational
age neonates; however, there were no significant benefits on maternal or newborn outcomes.
Taken together, a low-GI diet during early pregnancy can improve postprandial glucose and
weight gain, at least in some studies. However, these interventions are not adequate to prevent GDM
or to consistently reduce the incidence of LGA infants. Whether the type of CHO (low-GI or slowly
digesting and low-GI) or additional factors are necessary to offset the rapidly changing and complex
pathophysiology that occurs during pregnancy are unknown. Additional insight into the role of CHO
can be gained from observational studies that have investigated nutritional intakes and/or patterns
before or during pregnancy and GDM; these studies [68,69] show GDM is higher in those having
higher intakes of meat and a lower intake of whole grain carbohydrates, fruits, vegetables, and fish.
These studies suggest that CHO along with other dietary components are likely involved. A high
intake of saturated fat can interfere with insulin signaling, and they can also induce inflammation
and endothelial dysfunction, both pathogenic factors in GDM. Amino acids can act as substrates
for hepatic glucose production and in hepatic lipotoxicity. Although CHO such as fructose found
in fruit are lower GI, more slowly digesting CHO such as those found in whole grains can slow
sugar absorption, reducing the demand on cells and insulin signaling mediators. In addition, proper
intake of micronutrients and polyunsaturated fats, including those derived from fish and seafood,
have anti-inflammatory properties consistently associated with a reduced risk of GDM. Another key
consideration in all intervention studies is the ability of the women to adopt the intervention. In their
systematic review, Lammimpaa and coauthors concluded that variability in the delivery of dietary
interventions is a key factor affecting study outcomes in GDM. Thus, additional research on the benefits
of dietary CHO, with or without other nutritional factors, should also pay attention to the consistency
of its delivery [70].
5. Promising Approaches to Help Patients with GDM Adhere to Dietary Recommendations
GDM is a complex disease requiring patients to self-manage their diet, lifestyle, and self-care
behaviors in combination with use of insulin or, in some cases, oral medications such as metformin
or glyburide [71]. Trying to engage pregnant women with (or at risk of) GDM to change their diet is
especially challenging; although most women are especially attuned to the health of their developing
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fetus, food cravings, palatability, hunger and time pressure are cited as barriers to adherence to
prescribed diets [72].
Meal replacements can be helpful for people not only for being convenient, but also for providing
known calorie amounts with specific macro- and micro-nutrient levels that facilitate meal planning.
When used as part of lifestyle intervention in diabetes prevention programs, meal replacements have
been shown to promote weight loss and reduction in the incidence of type 2 diabetes in overweight/obese
people at increased risk of developing type 2 diabetes [73,74]. There is good evidence that meal
replacement as part of a lifestyle intervention is effective in promoting weight loss and improving
metabolic outcomes in individuals with type 2 diabetes [75,76] The current diabetes guidelines from the
American Diabetes Association [77], the Canadian Diabetes Association [78], and Diabetes UK [79] have
recommended the use of meal replacements in the management of individuals with diabetes.
The role of meal replacements in preventing the development of GDM has not been well studied.
Given the risk of pregnancy complications such as gestational diabetes, macrosomia and Cesarean
delivery, and the risk of adverse metabolic health outcomes associated with excessive gestational
weight gain (GWG), recently Phelan et al. [80] conducted an RCT involving 257 overweight and obese
pregnant women (mean± SD: 13.6± 1.8 weeks of gestation) to evaluate the effect of a behavioral lifestyle
intervention (n = 129) with partial meal replacement in comparison of enhanced usual care (n = 128)
on weekly gestational weight gain (GWG) rate, cardiovascular disease risk factors, and incidence of
pregnancy complications. Participants in the enhanced usual care group received all aspects of usual
care offered by their prenatal care providers. In addition, they were given the general information
about healthy eating, physical activity, and the Institute of Medicine (IOM) recommendations for
total gestational weight gain at the time of study randomization. The intervention group received all
aspects of enhanced usual care plus a behavioral lifestyle intervention designed to prevent excessive
weight gain during pregnancy. Each participant received a 20-min individual, face-to-face counseling
session with a study interventionist every two weeks until 20 weeks of gestation and then monthly
visits until delivery. To promote weight control, they were instructed to replace two meals with the
provided meal replacement shakes or bars and to consume ≥ 1 meal of regular foods and 2–4 healthy
snacks/day. The meal replacement products included organic and lactose-free drinks and bars in which
80% of the study’s meal replacements purchased were for organic meal replacement products high in
protein, 15% were for the bar also high in protein; and 4% were for powder meal replacement including
a standard oral nutritional supplement (4%) and a diabetes-specific formula (1%). The meal plan
using partial meal replacement provided a calorie intake of ~18 kcal/kg body weight at study entry in
which 30%, 15%–20% and 50–55% of calories were from fat, protein, and carbohydrates, respectively.
The intervention group had significantly lower weekly GWG rates compared with the control group
(0.33 vs 0.39 kg/week, respectively, p = 0.02). In addition, 43% women in the intervention group were
less likely to exceed the (IOM) recommendations for total GWG than were those in the control group
(OR: 0.57; 95% CI: 0.34, 0.95; P = 0.03). From study entry to 35–36 weeks of gestation, when compared
with the enhanced usual care, the intervention significantly reduced triglycerides (P = 0.03) and resulted
in trend reductions in fasting glucose (P = 0.09) and systolic blood pressure (P = 0.06). Regardless of
group assignment, greater increases in GWG rate were associated with increases in insulin (2.63 µU/mL;
95% CI: 1.63, 4.23 µU/mL; P < 0.0001), HOMA-IR (2.84; 95% CI: 1.67, 4.85; P < 0.0001), and C-peptide
(1.52 ng/mL; 95% CI: 1.15, 2.01 ng/mL; P < 0.0001). There were no significant differences between
groups in triglycerides, HDL cholesterol, LDL cholesterol, total cholesterol, diastolic blood pressure
and systolic blood pressure. The incidence of pregnancy complications was similar between groups.
The study has suggested that partial meal replacements as part of a behavioral lifestyle intervention
is effective for GWG control in women who are overweight and obese. There is a need for further
research on its effectiveness before it could be considered as part of the usual prenatal care for pregnant
women with obesity.
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5.1. Evidence for the Use of Complete and Balanced Nutritional Supplements Containing Low-Glycemic and
Slowly Digested Carbohydrates on GDM Outcomes
Specialized diabetes-specific formulas (DSF) are designed using low glycemic index and slowly
digested carbohydrates and monosaturated fatty acids to support glycemic control [81–83]. Systematic
reviews and meta-analyses have shown that DSF as part of lifestyle interventions effectively improves
glycemic control and reduces cardiometabolic risks [84,85]. The effects of DSF on blood glucose
management in women with GDM were investigated in a few studies. Yu et al. [86] conducted a
randomized, controlled, unblinded study to investigate the effects of a DSF on postprandial blood
glucose and pregnancy outcomes in Chinese women with GDM from October 2011 to January 2012.
A total of 69 women diagnosed with GDM around 26 weeks of gestation were randomized to the
intervention consisting of individualized dietary recommendations using DSF (n = 32) or receiving
individualized dietary recommendation only (n = 31), as the control group. The DSF was consumed
twice daily to replace regular milk during breakfast and a meal. The 2-h postprandial blood glucose
was measured weekly over a period of eight weeks from enrollment to the week prior to delivery.
When compared with the control group, the intervention group had significantly lower 2-h postprandial
blood glucose levels based on the General Linear Model Repeated Measures (P < 0.01) and significantly
lower HbA1c (5.5% vs. 5.7%; P < 0.05). Pregnancy outcomes were found to be in favour of the
intervention group in which the intervention had significantly lower incidences of premature rupture
of membranes (9.7% vs, 34.5%; P < 0.05), polyhydramnios (12.9% vs. 37.9%; P < 0.05), and neonatal
pneumonia (6.5% vs. 31.0%; P < 0.05), and significantly lower birth weight (3346 g vs. 3549 g;
P < 0.05) [86].
Liu et al. [87] evaluated the effects of a DSF on fasting blood glucose, 2-h postprandial blood
glucose, triglycerides and total cholesterol in a 2-week randomized, controlled trial on 40 GDM
pregnant women. All participants received individualized dietary counseling in which the total
calories were calculated to achieve an ideal body weight with 30–38 kcal/kg body weight. They were
instructed to consume six meals a day including three normal meals plus three extra meals to achieve
the target calories. For women in the intervention group (n = 20), a DSF was given in two extra meals
at 9:00 am and 3:00 pm. The calories from two servings of a DSF account for about 25% of total daily
calories. Women in the control group (n = 10) were instructed to select CHO such as skim milk, fruits
and oatmeal as part of a diabetes meal plan. There were no significant differences in 2-h postprandial
blood glucose (at 11 am) between the DSF (8.1 ± 0.9 mmol/L) and the control groups (8.4 ± 1.1 mmol/L)
at baseline. Both study groups showed a significant reduction in 2-h postprandial glucose levels
(at 11 am) from baseline after two weeks of intervention. However, the intervention group achieved a
significantly greater improvement compared with the control (6.6 ± 1.5 mmol/L and 7.1 ± 1.3 mmol/L,
respectively, between-group P < 0.05). Similar findings were observed for 2-h postprandial blood
glucose for the extra meal in the afternoon (at 5 pm). No differences in serum triglyceride and total
cholesterol concentrations were found after two weeks of intervention [87].
The effects of a DSF on blood glucose control were evaluated in another randomized, controlled
trial with nine weeks of intervention involving 70 Chinese GDM pregnant women [88]. Both the
intervention (n = 34) and the control (n = 36) groups received a diabetes diet in which the total
daily calories were distributed as follows: 10%, 30%, 30% and 30% for breakfast, lunch, dinner and
snacks, respectively. For the intervention group, a DSF was used as a snack replacement. Fasting
plasma glucose levels and 2-h postprandial blood glucose levels were measured on a weekly basis
over the period of nine weeks. There were some differences in fasting plasma glucose levels and 2-h
postprandial blood glucose levels between the groups over a 9-week period. However, it is unclear
if the intervention group had better glycemic control because the results of using a statistical test to
compare the differences was not mentioned [88].
Overall, there is evidence that use of a DSF as a partial meal or snack replacement in a diabetes
meal plan resulted in a greater improvement in glycemic control compared with dietary counseling
alone in women with GDM, suggesting it could be an effective treatment for glycemic control in
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GDM. There are also preliminary findings suggesting its benefits in reducing pregnancy and birth
complications. Further studies are needed to confirm this.
5.2. Application of Continuous Glucose Monitoring to Facilitate Close Monitoring of Diet on Glucose Control
A treatment goal for GDM to reduce maternal and perinatal outcomes is to maintain a fasting
glucose concentration of less than 90–95 mg/dL, one hour postprandial glucose level < 140 mg/dL or
2-h postprandial glucose level of < 120 mg/dL) [89]. The most popular method for daily blood glucose
control is self-monitoring blood glucose (SMBG), usually by fingerstick blood sampling at defined
times. Use of SMBG readings provide a limited number of measurements and insufficient information
of the blood sugar level changes. Recent technology, such as continuous glucose monitoring (CGM),
is a promising method for improving the glucose profile by giving a more complete view and thus
improving patient treatment and quality of life [90].
CGM comprises a subcutaneous glucose-sensing device and an electrode impregnated with
glucose oxidase that allows interstitial glucose levels to be measured approximately every ten seconds
and an average value is stored in the monitor every five minutes [90,91]. CGM is an effective tool in
the management of pregnant women with type 1 diabetes and has been shown to improve neonatal
outcomes. Feig et al., 2017 [92], in the multicenter, open-label, randomized controlled trial LANCET
study, examined the effectiveness CGM on maternal glucose control and obstetric and neonatal
health outcomes (n = 325 women). The authors concluded that the use of CGM during pregnancy is
associated with improved neonatal outcomes, which are likely to be attributed to reduced exposure to
maternal hyperglycemia.
Additional benefits of CGM include the ability to improve screening protocol [90]. Importantly,
the ability to understand normoglycemia and its patterns of variation in nondiabetic pregnant women
across the day can allow for future individualized therapies in these patients [93]. Yu et al., 2014 [94]
in a prospective cohort study evaluated the effectiveness of CGM on maternal glycemic control and
pregnancy outcome in 340 patients with GDM. Patients were allocated in two groups, 190 receiving a
routine care self-monitoring of blood glucose (SMBG) and other 150 following the CGM. They concluded
that the use of supplementary CGM can improve the glycemic variability and pregnancy outcomes in
patients with GDM.
In the last decade, some studies used the CGM technology to facilitate close monitoring of diet
on glucose control. Hernandez et al., 2014 [53], in a randomized crossover study, compared two
different types of diets (one higher in complex CHO/lower fat and other one lower-CHO/higher fat)
using CGM for 72 h to obtain glucose profiles in 16 GDM women. These data show that a diet high
in complex CHO and reduced fat still achieved glycemia below current treatment targets and lower
postprandial free fat acids. Subsequently, Carreiro et al., 2016 [95] used CGM to more accurately
assess the impact of dietary recommendations on women suffering from gestational diabetes and they
concluded that dietary counseling was able to keep glucose levels close to those of healthy patients.
In a prospective observational study with GDM patients two methods to evaluate glucose readings,
CGM and self-monitor blood sugar glucose (SMBG), during Ramadan fasting were compared [96].
They concluded that CGM was effective to detect more hypoglycemia than SMBG in GDM patients.
Although limited, studies have shown that CGM systems have the potential to help the patient and
their health care providers manage their day-to-day diet, lifestyle, self-care and medication decisions
to achieve treatment goals. However, more research is needed to understand its full potential on both
mother and infant outcomes.
6. Conclusions
Nutrition is critical to the prevention and treatment of GDM for the health and well-being of both
mother and offspring. Close attention to the amount and type of dietary CHO can have important
benefits on GDM pathophysiology, but interventions as currently implemented may not be adequate
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to prevent or treat this complex disease. Continued research is needed to develop tools to facilitate
patient adherence to treatment goals, individualize interventions and improve the results.
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effectiveness, tolerability and safety of high and low carbohydrate diets in women with gestational diabetes.
Endokrynol. Polska 2007, 58, 314–319.
52. Moreno-Castilla, C.; Hernandez, M.; Bergua, M.; Alvarez, M.C.; Arce, M.A.; Rodriguez, K.;
Martinez-Alonso, M.; Iglesias, M.; Mateu, M.; Santos, M.D.; et al. Low-carbohydrate diet for the treatment of
gestational diabetes mellitus: A randomized controlled trial. Diabetes Care 2013, 36, 2233–2238. [CrossRef]
[PubMed]
53. Hernandez, T.L.; Van Pelt, R.E.; Anderson, M.A.; Daniels, L.J.; West, N.A.; Donahoo, W.T.; Friedman, J.E.;
Barbour, L.A. A Higher-Complex Carbohydrate Diet in Gestational Diabetes Mellitus Achieves Glucose
Targets and Lowers Postprandial Lipids: A Randomized Crossover Study. Diabetes Care 2014, 37, 1254–1262.
[CrossRef]
54. Ma, W.-J.; Huang, Z.-H.; Huang, B.-X.; Qi, B.-H.; Zhang, Y.-J.; Xiao, B.-X.; Li, Y.-H.; Chen, L.; Zhu, H.-L.
Intensive low-glycaemic-load dietary intervention for the management of glycaemia and serum lipids among
women with gestational diabetes: A randomized control trial. Public Health Nutr. 2014, 18, 1506–1513.
[CrossRef]
55. Grant, S.M.; Wolever, T.M.; O’Connor, D.L.; Nisenbaum, R.; Josse, R.G. Effect of a low glycaemic index diet on
blood glucose in women with gestational hyperglycaemia. Diabetes Res. Clin. Pr. 2011, 91, 15–22. [CrossRef]
Nutrients 2020, 12, 385 15 of 17
56. Moses, R.G.; Barker, M.; Winter, M.; Petocz, P.; Brand-Miller, J.C. Can a low-glycemic index diet reduce
the need for insulin in gestational diabetes mellitus? A randomized trial. Diabetes Care 2009, 32, 996–1000.
[CrossRef] [PubMed]
57. Perichart-Perera, O.; Balas-Nakash, M.; Rodríguez-Cano, A.; Legorreta-Legorreta, J.; Parra-Covarrubias, A.;
Vadillo-Ortega, F. Low Glycemic Index Carbohydrates versus All Types of Carbohydrates for Treating Diabetes
in Pregnancy: A Randomized Clinical Trial to Evaluate the Effect of Glycemic Control. Int. J. Endocrinol.
2012, 2012, 1–10. [CrossRef]
58. Louie, J.C.Y.; Markovic, T.P.; Perera, N.; Foote, D.; Petocz, P.; Ross, G.P.; Brand-Miller, J.C. A Randomized
Controlled Trial Investigating the Effects of a Low–Glycemic Index Diet on Pregnancy Outcomes in Gestational
Diabetes Mellitus. Diabetes Care 2011, 34, 2341–2346. [CrossRef] [PubMed]
59. Dodd, J.M.; For the LIMIT Randomised Trial Group; Cramp, C.; Sui, Z.; Yelland, L.N.; Deussen, A.R.;
Grivell, R.M.; Moran, L.J.; A Crowther, C.; Turnbull, D.; et al. The effects of antenatal dietary and lifestyle
advice for women who are overweight or obese on maternal diet and physical activity: The LIMIT randomised
trial. BMC Med. 2014, 12, 161. [CrossRef] [PubMed]
60. Markovic, T.P.; Muirhead, R.; Overs, S.; Ross, G.P.; Louie, J.C.Y.; Kizirian, N.; Denyer, G.; Petocz, P.; Hyett, J.;
Brand-Miller, J.C. Randomized Controlled Trial Investigating the Effects of a Low-Glycemic Index Diet
on Pregnancy Outcomes in Women at High Risk of Gestational Diabetes Mellitus: The GI Baby 3 Study.
Diabetes Care 2016, 39, 31–38. [CrossRef] [PubMed]
61. Walsh, J.M.; McGowan, C.A.; Mahony, R.; Foley, M.E.; McAuliffe, F.M. Low glycaemic index diet in pregnancy
to prevent macrosomia (ROLO study): Randomised control trial. BMJ 2012, 345, e5605. [CrossRef]
62. Poston, L.; Bell, R.; Croker, H.; Flynn, A.C.; Godfrey, K.M.; Goff, L.; Hayes, L.; Khazaezadeh, N.; Nelson, S.M.;
Oteng-Ntim, E.; et al. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): A
multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2015, 3, 767–777. [CrossRef]
63. Han, S.; Middleton, P.; Shepherd, E.; Van Ryswyk, E.; Crowther, C.A. Different types of dietary advice for
women with gestational diabetes mellitus. Cochrane Database Syst. Rev. 2017, 2017, CD009275. [CrossRef]
[PubMed]
64. Yamamoto, J.M.; Kellett, J.E.; Balsells, M.; García-Patterson, A.; Hadar, E.; Sola, I.; Gich, I.; Van Der Beek, E.M.;
Castañeda-Gutiérrez, E.; Heinonen, S.; et al. Gestational Diabetes Mellitus and Diet: A Systematic Review
and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions
on Maternal Glucose Control and Neonatal Birth Weight. Diabetes Care 2018, 41, 1346–1361. [CrossRef]
[PubMed]
65. Wan, C.S.; Nankervis, A.; Teede, H.; Aroni, R. Dietary intervention strategies for ethnic Chinese women
with gestational diabetes mellitus: A systematic review and meta-analysis. Nutr. Diet. 2019, 76, 211–232.
[CrossRef]
66. Tieu, J.; Shepherd, E.; Middleton, P.; Crowther, C.A. Dietary advice interventions in pregnancy for preventing
gestational diabetes mellitus. Cochrane Database Syst. Rev. 2017, 2017, CD006674. [CrossRef]
67. Zhang, R.; Han, S.; Chen, G.-C.; Li, Z.-N.; Silva-Zolezzi, I.; Parés, G.V.; Wang, Y.; Qin, L.Q. Effects
of low-glycemic-index diets in pregnancy on maternal and newborn outcomes in pregnant women: A
meta-analysis of randomized controlled trials. Eur. J. Nutr. 2018, 57, 167–177. [CrossRef]
68. Schoenaker, D.A.; Mishra, G.D.; Callaway, L.K.; Soedamah-Muthu, S.S. The Role of Energy, Nutrients,
Foods, and Dietary Patterns in the Development of Gestational Diabetes Mellitus: A Systematic Review of
Observational Studies. Diabetes Care 2016, 39, 16–23. [CrossRef]
69. Zhou, X.; Chen, R.; Zhong, C.; Wu, J.; Li, X.; Li, Q.; Cui, W.; Yi, N.; Xiao, M.; Yin, H.; et al. Maternal dietary
pattern characterised by high protein and low carbohydrate intake in pregnancy is associated with a higher
risk of gestational diabetes mellitus in Chinese women: A prospective cohort study. Br. J. Nutr. 2018, 120,
1045–1055. [CrossRef]
70. Lamminpää, R.; Vehviläinen-Julkunen, K.; Schwab, U. A systematic review of dietary interventions for
gestational weight gain and gestational diabetes in overweight and obese pregnant women. Eur. J. Nutr.
2018, 57, 1721–1736. [CrossRef]
71. Mack, L.R.; Tomich, P.G. Gestational Diabetes: Diagnosis, Classification, and Clinical Care. Obstet. Gynecol.
Clin. N. Am. 2017, 44, 207–217. [CrossRef]
72. Carolan, M.; Gill, G.K.; Steele, C. Women’s experiences of factors that facilitate or inhibit gestational diabetes
self-management. BMC Pregnancy Childbirth 2012, 12, 99. [CrossRef] [PubMed]
Nutrients 2020, 12, 385 16 of 17
73. Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A.; Nathan, D.M.
Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle
intervention or metformin. N. Engl. J. Med. 2002, 346, 393–403. [PubMed]
74. Lindström, J.; Tuomilehto, J. The diabetes risk score: A practical tool to predict type 2 diabetes risk.
Diabetes Care 2003, 26, 725–731. [CrossRef] [PubMed]
75. Hamdy, O.; Mottalib, A.; Morsi, A.; El-Sayed, N.; Goebel-Fabbri, A.; Arathuzik, G.; Shahar, J.; Kirpitch, A.;
Zrebiec, J. Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with
diabetes in real-world clinical practice: A 5-year longitudinal study. BMJ Open Diabetes Res. Care 2017, 5,
e000259. [CrossRef] [PubMed]
76. Wing, R.R.; AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and
cardiovascular risk factors in individuals with type 2 diabetes mellitus; four year results of the look
AHEAD trial. Arch. Intern. Med. 2010, 170, 1566–1575. [PubMed]
77. American Diabetes Association. Obesity management for the treatment of type 2 diabetes: Standards of
Medical Care in Diabetes-2020. Diabetes Care. 2020, 43 (Suppl. 1), S89–S97. [CrossRef]
78. Sievenpiper, J.L.; Chan, C.B.; Dworatzek, P.D.; Freeze, C.; Williams, S.L. Diabetes Canada Clinical Practice
Guidelines Expert Committee. Nutr. Ther. Can. J. Diabetes 2018, 42 (Suppl. 1), S64–S79. [CrossRef]
79. Dyson, P.A.; Twenefour, D.; Breen, C.; Duncan, A.; Elvin, E.; Goff, L.; Hill, A.; Kalsi, P.; Marsland, N.;
McArdle, P.; et al. Diabetes UK evidence-based nutrition guidelines for the prevention and management of
diabetes. Diabet. Med. 2018, 35, 541–547. [CrossRef]
80. Phelan, S.; Wing, R.R.; Brannen, A.; McHugh, A.; Hagobian, T.A.; Schaffner, A.; Jelalian, E.; Hart, C.N.;
Scholl, T.O.; Munoz-Christian, K.; et al. Randomized controlled clinical trial of behavioral lifestyle intervention
with partial meal replacement to reduce excessive gestational weight gain. Am. J. Clin. Nutr. 2018, 107,
183–194. [CrossRef]
81. Voss, A.C.; Maki, K.C.; Garvey, W.T.; Hustead, D.S.; Alish, C.; Fix, B.; Mustad, V.A. Effect of two
carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes.
Nutrition 2008, 24, 990–997. [CrossRef]
82. Devitt, A.A.; Oliver, J.S.; Hegazi, R.A.; Mustad, V.A. Glycemia Targeted Specialized Nutrition (GTSN)
improves postprandial glycemia and GLP-1 with similar appetitive responses compared to a healthful whole
food breakfast in persons with type 2 diabetes: A randomized, controlled trial. J. Diabetes Res. Clin. Metab.
2012, 1, 20. [CrossRef]
83. Mottalib, A.; Mohd-Yusof, B.-N.; Shehabeldin, M.; Pober, D.M.; Mitri, J.; Hamdy, O. Impact of Diabetes-Specific
Nutritional Formulas versus Oatmeal on Postprandial Glucose, Insulin, GLP-1 and Postprandial Lipidemia.
Nutrients 2016, 8, 443. [CrossRef] [PubMed]
84. Ojo, O.; Ojo, O.O.; Adebowale, F.; Wang, X.-H. The Effect of Dietary Glycaemic Index on Glycaemia in
Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Nutrients 2018, 10, 373. [CrossRef] [PubMed]
85. Elia, M.; Ceriello, A.; Laube, H.; Sinclair, A.J.; Engfer, M.; Stratton, R.J. Enteral nutritional support and use of
diabetes-specific formulas for patients with diabetes: A systematic review and meta-analysis. Diabetes Care.
2005, 28, 2267–2279. [CrossRef]
86. Yu, X.-Y.; Zhang, H. [Effects of a nutritional liquid supplement designed for diabetes mellitus on postprandial
glucose and pregnancy outcomes in patients with gestational diabetes mellitus]. Zhonghua Yi Xue Za Zhi
2013, 93, 3450–3453.
87. Liu, J.; Zhu, W. Effects of Glucerna SR on blood glucose levels and relevant biochemical parameters in
patients with gestational diabetes mellitus. Laser J. 2013, 34, 75.
88. Li, X. Effects of Abbott Glucerna SR on controlling the blood glucose levels of 34 women with gestational
diabetes. Chin. J. Trauma Disabil. Med. 2013, 21, 245–246.
89. Crowther, C.A.; Hiller, J.E.; Moss, J.R.; McPhee, A.J.; Jeffries, W.S.; Robinson, J.S.; The Australian Carbohydrate
Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes
mellitus on pregnancy outcomes. N. Engl. J. Med. 2005, 352, 2477–2486. [CrossRef]
90. Byrne, E.Z.; Zisser, H.C.; Jovanovic, L. Continuous glucose monitoring: Is it helpful in pregnancy?
Curr. Diabetes Rev. 2008, 4, 223–226. [CrossRef]
91. Bailey, T.S.; Zisser, H.C.; Garg, S.K. Reduction in Hemoglobin A1c with Real-Time Continuous Glucose
Monitoring: Results from a 12-Week Observational Study. Diabetes Technol. Ther. 2007, 9, 203–210. [CrossRef]
Nutrients 2020, 12, 385 17 of 17
92. Feig, D.S.; Donovan, L.E.; Corcoy, R.; Murphy, K.E.; Amiel, S.A.; Hunt, K.F.; Asztalos, E.; Barrett, J.F.R.;
Sanchez, J.J.; De Leiva, A.; et al. Continuous glucose monitoring in pregnant women with type 1 diabetes
(CONCEPTT): A multicentre international randomised controlled trial. Lancet 2017, 390, 2347–2359.
[CrossRef]
93. González-Quintero, V.H.; Istwan, N.B.; Rhea, D.J.; Rodriguez, L.I.; Cotter, A.; Carter, J.; Mueller, A.;
Stanziano, G.J. The Impact of Glycemic Control on Neonatal Outcome in Singleton Pregnancies Complicated
by Gestational Diabetes. Diabetes Care 2007, 30, 467–470. [CrossRef] [PubMed]
94. Yu, F.; Weng, J.; Lv, L.; Liang, Z.; Wang, Y.; Wen, J.; Lin, X.; Zhou, Y.; Mai, C.; Niu, J. Continuous Glucose
Monitoring Effects on Maternal Glycemic Control and Pregnancy Outcomes in Patients with Gestational
Diabetes Mellitus: A Prospective Cohort Study. J. Clin. Endocrinol. Metab. 2014, 99, 4674–4682. [CrossRef]
[PubMed]
95. Carreiro, M.P.; Lauria, M.W.; Naves, G.N.T.; Miranda, P.A.C.; Leite, R.B.; Rajão, K.M.A.B.; De Aguiar, R.A.L.P.;
Nogueira, A.I.; Ribeiro-Oliveira, A. Seventy two-hour glucose monitoring profiles in mild gestational diabetes
mellitus: Differences from healthy pregnancies and influence of diet counseling. Eur. J. Endocrinol. 2016, 175,
201–209. [CrossRef]
96. Afandi, B.; Hassanein, M.; Roubi, S.; Nagelkerke, N. The value of Continuous Glucose Monitoring and
Self-Monitoring of Blood Glucose in patients with Gestational Diabetes Mellitus during Ramadan fasting.
Diabetes Res. Clin. Pr. 2019, 151, 260–264. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
